Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs ENT 01 (Primary)
  • Indications Constipation; Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KARMET
  • Sponsors Enterin
  • Most Recent Events

    • 09 Jan 2019 According to an Enterin media release, this study is a follow up to successful Phase 2a study (the RASMET study).
    • 09 Jan 2019 According to an Enterin media release, the company began screening patients for this study. Dr. Goldstein of Atlantis, Florida, and Dr. Kadimi of Fairfield, Connecticut, have both enrolled.
    • 21 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top